Publications:14
Brian D Radbill, MD
About Me
In the News
Dr. Radbill discusses chronic kidney disease in The Daily News feature The Daily Check Up.
View the PDF.
Language
English
Position
ASSOCIATE PROFESSOR | Medicine, Nephrology
Education
BA, University of Michigan
MD, Hahnemann University School of Medicine
, Mount Sinai School of Medicine
, Mount Sinai School of Medicine
Research
Previously published data suggests that short daily hemodialysis (2-2.5 hours a day, 6 days a week) may be superior to conventional hemodialysis (3-4 hours a day, 3 days a week) in terms of solute clearance and fluid management. Daily hemodialysis could result in improved dialysis adequacy, improved blood pressure control, decreased cardiac disease (specifically, left ventricular hypertrophy), and decreased mortality. We are working with RRI (Renal Research Institute) as part of a multi-center NIH funded clinical trial studying the potential benefits of short daily hemodialysis versus conventional hemodialysis.
Publications
Selected Publications
- The Impact of Bedside Interdisciplinary Rounds on Length of Stay and Complications. Andrew S. Dunn, Maria Reyna, Brian Radbill, Michael Parides, Claudia Colgan, Tobi Osio, Ari Benson, Nicole Brown, Joy Cambe, Margo Zwerling, Natalia Egorova, Harold Kaplan. Journal of Hospital Medicine
- Data-driven identification of risk factors of patient satisfaction at a large urban academic medical center. Li Li, Nathan J. Lee, Benjamin S. Glicksberg, Brian D. Radbill, Joel T. Dudley. PLoS ONE
- Effect of cholecalciferol supplementation on inflammation and cellular alloimmunity in hemodialysis patients: Data from a randomized controlled pilot trial. Lily Li, Marvin Lin, Maria Krassilnikova, Katya Ostrow, Amanda Bader, Brian Radbill, Jaime Uribarri, Joji Tokita, Staci Leisman, Vijay Lapsia, Randy A. Albrecht, Adolfo García-Sastre, Andrea D. Branch, Peter S. Heeger, Anita Mehrotra. PLoS ONE
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Radbill has not yet completed reporting of industry relationships or has no industry relationships to report.
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.